

# Nigel H Greig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3847583/publications.pdf>

Version: 2024-02-01

258  
papers

20,228  
citations

9254

74  
h-index

13365

130  
g-index

269  
all docs

269  
docs citations

269  
times ranked

20977  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2023, 30, 255-270.	1.2	5
2	Inhibition of Caspase 3 and Caspase 9 Mediated Apoptosis: A Multimodal Therapeutic Target in Traumatic Brain Injury. <i>Current Neuropharmacology</i> , 2023, 21, 1001-1012.	1.4	17
3	Improved post-stroke spontaneous recovery by astrocytic extracellular vesicles. <i>Molecular Therapy</i> , 2022, 30, 798-815.	3.7	17
4	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2022, 19, 305-324.	2.1	3
5	In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 70-79.	2.5	5
6	Diphtheria toxin induced but not CSF1R inhibitor mediated microglia ablation model leads to the loss of CSF/ventricular spaces in vivo that is independent of cytokine upregulation. <i>Journal of Neuroinflammation</i> , 2022, 19, 3.	3.1	13
7	Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. <i>Alzheimer's and Dementia</i> , 2022, 18, 2327-2340.	0.4	51
8	Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment. <i>Current Medicinal Chemistry</i> , 2022, 29, 5289-5314.	1.2	7
9	3,6- and 1,6-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. <i>Pharmaceutics</i> , 2022, 14, 950.	2.0	3
10	Age-related impairment of cerebral blood flow response to K <sup>ATP</sup> channel opener in Alzheimer's disease mice with presenilin-1 mutation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1579-1591.	2.4	8
11	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 858-869.	2.5	12
12	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 656921.	1.4	16
13	N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 980-1000.	2.5	14
14	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 536257.	1.3	53
15	Thionation of Aminophthalimide Hindered Carbonyl Groups and Application to the Synthesis of 3,6-Dithionated Pomalidomides. <i>Synlett</i> , 2021, 32, 917-922.	1.0	7
16	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. <i>Cells</i> , 2021, 10, 993.	1.8	37
17	High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15. <i>Antibiotics</i> , 2021, 10, 474.	1.5	10
18	nAChRs gene expression and neuroinflammation in APP <sup>swe</sup> /PS1 <sup>dE9</sup> transgenic mouse. <i>Scientific Reports</i> , 2021, 11, 9711.	1.6	8

#	ARTICLE	IF	CITATIONS
19	3,6-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astrogliosis and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8276.	1.8	10
20	The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. <i>Journal of Neurochemistry</i> , 2021, 159, 867-886.	2.1	18
21	Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins. <i>FASEB Journal</i> , 2020, 34, 3359-3366.	0.2	54
22	Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2020, 324, 113113.	2.0	16
23	( $\alpha$ )-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 636-649.	1.9	12
24	The p53 inactivators pifithrin-1/4 and pifithrin-1 $\pm$ mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy. <i>Experimental Neurology</i> , 2020, 324, 113135.	2.0	33
25	PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 785.	1.4	15
26	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , 2020, 25, 5683.	1.7	11
27	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 595-602.	1.9	34
28	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 31.	1.7	13
29	Rivastigmine modifies the 1 $\pm$ -secretase pathway and potentially early Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 47.	2.4	44
30	Post-treatment with Posiphen Reduces Endoplasmic Reticulum Stress and Neurodegeneration in Stroke Brain. <i>IScience</i> , 2020, 23, 100866.	1.9	9
31	3,6-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. <i>ELife</i> , 2020, 9, .	2.8	24
32	Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury. <i>ELife</i> , 2020, 9, .	2.8	21
33	Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 975-987.	1.7	42
34	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. <i>Neurobiology of Disease</i> , 2019, 130, 104528.	2.1	33
35	Immunomodulatory drugs alleviate L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1818-1830.	2.2	44
36	Neuronal Hyperexcitability Following mTBI. , 2019, , 67-81.		0

#	ARTICLE	IF	CITATIONS
37	Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6-Dithiothalidomide on Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , 2019, 20, 502.	1.8	21
38	(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. <i>Cell Transplantation</i> , 2019, 28, 1183-1196.	1.2	11
39	Is insulin resistance the cause of fibromyalgia? A preliminary report. <i>PLoS ONE</i> , 2019, 14, e0216079.	1.1	6
40	Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. <i>Neurotoxicity Research</i> , 2019, 36, 347-356.	1.3	11
41	Pomalidomide Reduces Ischemic Brain Injury in Rodents. <i>Cell Transplantation</i> , 2019, 28, 439-450.	1.2	14
42	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. <i>Future Medicinal Chemistry</i> , 2019, 11, 489-493.	1.1	29
43	Can We Prevent Dementia and Not Prevent Neurons from Dying?. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 489-492.	1.2	3
44	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 66-91.	2.5	28
45	Mitophagy inhibits amyloid- $\beta^2$ and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. <i>Nature Neuroscience</i> , 2019, 22, 401-412.	7.1	1,008
46	Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid- $\beta^2$ Pathology in Female Rhesus Macaques ( <i>Macaca Mulatta</i> ). <i>Journal of Alzheimer's Disease</i> , 2019, 68, 115-126.	1.2	9
47	Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis. <i>Trends in Neurosciences</i> , 2019, 42, 151-163.	4.2	27
48	Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patients. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 3-18.	1.0	1
49	Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. <i>Scientific Reports</i> , 2019, 9, 17208.	1.6	16
50	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 313.	1.8	91
51	Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. <i>Neurobiology of Disease</i> , 2019, 124, 439-453.	2.1	25
52	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 420.	4.5	169
53	A Pilot Study of Exenatide Actions in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 741-752.	0.7	75
54	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 356.	1.8	29

#	ARTICLE	IF	CITATIONS
55	Neuroprotective effects of pifithrin- $\alpha$ against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. <i>Scientific Reports</i> , 2018, 8, 2368.	1.6	52
56	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF- $\alpha$ and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1547-1559.	1.4	14
57	Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?. <i>Alzheimer's and Dementia</i> , 2018, 14, 431-443.	0.4	28
58	P3 $\alpha$ 061: CONSTITUTIVE IN VIVO OVEREXPRESSION OF MIR146A AND MIR200B INDEPENDENTLY MODULATES LEVELS OF ALZHEIMER'S DISEASE (AD) $\alpha$ -RELATED PROTEINS IN THE MOUSE HIPPOCAMPUS AND CEREBRAL CORTEX. <i>Alzheimer's and Dementia</i> , 2018, 14, P1088.	0.4	0
59	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. <i>VirusDisease</i> , 2018, 29, 419-433.	1.0	9
60	P3 $\alpha$ 053: ( $\alpha$ ) $\alpha$ -PHENSERINE (PHEN) AND THE PREVENTION OF PRE $\alpha$ -PROGRAMMED CELL DEATH IN ALZHEIMER'S DISEASE (AD) AND MILD TRAUMATIC BRAIN INJURY (MTBI). <i>Alzheimer's and Dementia</i> , 2018, 14, P1083.	0.4	0
61	Pomalidomide Ameliorates H <sub>2</sub> O <sub>2</sub> -Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3252.	1.8	24
62	Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1153.	1.8	13
63	Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?. <i>Neuropharmacology</i> , 2018, 136, 159.	2.0	3
64	Sequential combined Treatment of Pifithrin- $\alpha$ and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke. <i>Cell Transplantation</i> , 2018, 27, 607-621.	1.2	7
65	The Role of microRNAs in Alzheimer $\alpha$ 's Disease and Their Therapeutic Potentials. <i>Genes</i> , 2018, 9, 174.	1.0	90
66	Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson $\alpha$ 's disease. <i>Scientific Reports</i> , 2018, 8, 10722.	1.6	44
67	Neuroinflammation and ER-stress are key mechanisms of acute bilirubin toxicity and hearing loss in a mouse model. <i>PLoS ONE</i> , 2018, 13, e0201022.	1.1	56
68	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer $\alpha$ 's Disease. <i>Current Alzheimer Research</i> , 2018, 15, 883-891.	0.7	15
69	GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR6-4.	0.0	0
70	Inhibition of butyrylcholinesterase improves prepulse inhibition deficits and enhances M1 muscarinic acetylcholine receptor-mediated responses via ghrelin signaling in mice. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-1-134.	0.0	0
71	Posiphen $\alpha$ “ a new experimental drug to understand and mitigate age-related neurodegenerative disorders. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY54-3.	0.0	0
72	Novel GLP-1R/GIPR co-agonist $\alpha$ “etwincretin $\alpha$ 's neuroprotective in cell and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2017, 288, 176-186.	2.0	34

#	ARTICLE	IF	CITATIONS
73	Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms. Trends in Neurosciences, 2017, 40, 151-166.	4.2	553
74	Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity. Neurotoxicity Research, 2017, 32, 218-230.	1.3	10
75	Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain, 2017, 140, 1420-1436.	3.7	80
76	( $\alpha^7$ )-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury. Brain Research, 2017, 1677, 118-128.	1.1	31
77	Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Scientific Reports, 2017, 7, 3735.	1.6	39
78	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	6.3	527
79	Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders. Journal of Biological Chemistry, 2017, 292, 20353.	1.6	6
80	Drug discovery and development: Role of basic biological research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 651-657.	1.8	330
81	A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis. Cell Transplantation, 2017, 26, 1560-1571.	1.2	111
82	Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Experimental Neurology, 2017, 288, 104-113.	2.0	23
83	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2017, 9, 77.	1.7	42
84	Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives. Current Alzheimer Research, 2017, 14, 1138-1139.	0.7	1
85	Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. Journal of Biomedical Science, 2017, 24, 71.	2.6	29
86	Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases. Current Pharmaceutical Design, 2017, 23, 1571-1574.	0.9	3
87	Adiponectin as a Potential Therapeutic Target for Prostate Cancer. Current Pharmaceutical Design, 2017, 23, 4170-4179.	0.9	27
88	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. Current Alzheimer Research, 2017, 14, 1190-1197.	0.7	39
89	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. Current Alzheimer Research, 2017, 14, 1164-1181.	0.7	57
90	Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. CNS and Neurological Disorders - Drug Targets, 2017, 16, 820-827.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2016, 22, 2923-2925.	0.9	3
92	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq0 0 0 rgBT /Overlock 10 2016, 22, 4337-4340.	0.9	1
93	Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. Journal of Neuroinflammation, 2016, 13, 168.	3.1	39
94	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq0 0 0 rgBT /Overlock 10 515-517.	0.9	4
95	Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. Journal of Neurochemistry, 2016, 138, 746-757.	2.1	38
96	Neuroinflammation in animal models of traumatic brain injury. Journal of Neuroscience Methods, 2016, 272, 38-49.	1.3	195
97	Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. Journal of Neurotrauma, 2016, 33, 2044-2054.	1.7	31
98	Post-traumatic administration of the p53 inactivator pifithrin- $\alpha$ oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury. Neurobiology of Disease, 2016, 96, 216-226.	2.1	34
99	Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. Cell Metabolism, 2016, 24, 332-340.	7.2	375
100	Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. Journal of Neuroscience Methods, 2016, 272, 69-76.	1.3	18
101	Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. Journal of Neuroscience Methods, 2016, 272, 4-18.	1.3	28
102	Transgenerational latent early-life associated regulation unites environment and genetics across generations. Epigenomics, 2016, 8, 373-387.	1.0	20
103	Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. Alzheimer's and Dementia, 2016, 12, 34-48.	0.4	48
104	Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. PLoS ONE, 2016, 11, e0156493.	1.1	36
105	<i>In vivo</i> screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget, 2016, 7, 33237-33245.	0.8	44
106	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. Current Pharmaceutical Design, 2016, 22, 527-534.	0.9	57
107	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Current Pharmaceutical Design, 2016, 22, 4360-4373.	0.9	53
108	miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. Medicinal Chemistry, 2016, 12, 217-225.	0.7	57

#	ARTICLE	IF	CITATIONS
109	miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 563-580.	1.2	107
110	Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , 2015, 135, 1203-1217.	2.1	76
111	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 12, 32-46.	0.7	255
112	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , 2015, 2, 756-764.	3.7	16
113	Transiently lowering tumor necrosis factor- $\alpha$ synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neuroinflammation</i> , 2015, 12, 45.	3.1	107
114	Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. <i>Experimental Neurology</i> , 2015, 273, 151-160.	2.0	43
115	(-)-Phenserine Attenuates Soman-Induced Neuropathology. <i>PLoS ONE</i> , 2014, 9, e99818.	1.1	14
116	Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration. <i>PLoS ONE</i> , 2014, 9, e104973.	1.1	58
117	Lessons from a BACE1 inhibitor trial: Off-site but not off base. <i>Alzheimer's and Dementia</i> , 2014, 10, S411-9.	0.4	69
118	Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. , 2014, 10, S62-S75.		64
119	A new roadmap for drug development for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 156-156.	21.5	54
120	Critical role of TNF- $\alpha$ in cerebral aneurysm formation and progression to rupture. <i>Journal of Neuroinflammation</i> , 2014, 11, 77.	3.1	103
121	Amyloid- $\beta$ precursor protein synthesis inhibitors for Alzheimer's disease treatment. <i>Annals of Neurology</i> , 2014, 76, 629-630.	2.8	5
122	Evidence of a Novel Mechanism for Partial $\beta$ -Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid $\beta$ Protein. <i>PLoS ONE</i> , 2014, 9, e91531.	1.1	19
123	Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid- $\beta$ ; Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway. <i>Current Alzheimer Research</i> , 2014, 11, 608-622.	0.7	45
124	A New Regulatory Road-Map for Alzheimer's Disease Drug Development. <i>Current Alzheimer Research</i> , 2014, 11, 215-220.	0.7	18
125	Linking Alzheimer's Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 338-346.	0.8	24
126	Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1280-1293.	0.8	138



#	ARTICLE	IF	CITATIONS
127	Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1432-1439.	0.8	209
128	Exploring N <sup>1</sup> -p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 197-202.	0.8	3
129	Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. <i>Age</i> , 2013, 35, 1621-1636.	3.0	83
130	Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. <i>Neurobiology of Disease</i> , 2013, 54, 1-11.	2.1	75
131	TNF- $\alpha$ Induces Phenotypic Modulation in Cerebral Vascular Smooth Muscle Cells: Implications for Cerebral Aneurysm Pathology. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1564-1573.	2.4	133
132	Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. <i>Experimental Neurology</i> , 2013, 239, 170-182.	2.0	80
133	Fire in the ashes: Can failed Alzheimer's disease drugs succeed with second chances?. <i>Alzheimer's and Dementia</i> , 2013, 9, 50-57.	0.4	32
134	3,6- $\epsilon$ -dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. <i>Journal of Neuroscience Research</i> , 2013, 91, 671-680.	1.3	38
135	Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4820.	3.3	8
136	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12703-12708.	3.3	64
137	Neurotrophic and Neuroprotective Actions of ( $\alpha$ )- and (+)-Phenserine, Candidate Drugs for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e54887.	1.1	50
138	Cognitive Impairments Accompanying Rodent Mild Traumatic Brain Injury Involve p53-Dependent Neuronal Cell Death and Are Ameliorated by the Tetrahydrobenzothiazole PFT- $\alpha$ . <i>PLoS ONE</i> , 2013, 8, e79837.	1.1	67
139	Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats. <i>PLoS ONE</i> , 2013, 8, e82016.	1.1	56
140	Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid- $\beta$ Levels. <i>PLoS ONE</i> , 2013, 8, e58752.	1.1	36
141	New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors. <i>Recent Patents on CNS Drug Discovery</i> , 2013, 8, 123-141.	0.9	32
142	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, $\beta$ -Synuclein Synthesis, Interleukin-1 $\beta$ Release, and Cholinergic Action.. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 117-128.	1.1	23
143	Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF- $\alpha$ , p38 Kinase and JNK Kinase. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 129-135.	1.1	9
144	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- $\beta$ peptide and $\beta$ , levels: target engagement, tolerability and pharmacokinetics in humans. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 894-902.	0.9	66

#	ARTICLE	IF	CITATIONS
145	N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer's Disease, Vascular Dementia and Parkinson's Disease. <i>Current Alzheimer Research</i> , 2012, 9, 746-758.	0.7	277
146	Was Phenserine a Failure or Were Investigators Mislead by Methods?. <i>Current Alzheimer Research</i> , 2012, 9, 1174-1181.	0.7	18
147	Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 482-489.	0.8	39
148	Roles of p75NTR, Long-Term Depression, and Cholinergic Transmission in Anxiety and Acute Stress Coping. <i>Biological Psychiatry</i> , 2012, 71, 75-83.	0.7	43
149	Kinetics of <i>Torpedo californica</i> acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. <i>Biochemical Journal</i> , 2012, 444, 269-277.	1.7	22
150	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. <i>British Journal of Pharmacology</i> , 2012, 166, 1586-1599.	2.7	200
151	3,6-dithiothalidomide, a new TNF- $\alpha$ synthesis inhibitor, attenuates the effect of A $\beta$ <sup>1-42</sup> intracerebroventricular injection on hippocampal neurogenesis and memory deficit. <i>Journal of Neurochemistry</i> , 2012, 122, 1181-1192.	2.1	61
152	Tumor necrosis factor- $\alpha$ synthesis inhibitor 3,6-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 106.	3.1	179
153	Early intervention with a small molecule inhibitor for tumor necrosis factor- $\alpha$ prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 99.	3.1	79
154	Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2012, 7, e32008.	1.1	101
155	The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5'-Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. <i>Parkinson's Disease</i> , 2012, 2012, 1-13.	0.6	37
156	Exendin-4 decreases amphetamine-induced locomotor activity. <i>Physiology and Behavior</i> , 2012, 106, 574-578.	1.0	74
157	TNF- $\alpha$ protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. <i>Journal of Neuroinflammation</i> , 2012, 9, 23.	3.1	224
158	Acetylcholinesterase inhibition ameliorates deficits in motivational drive. <i>Behavioral and Brain Functions</i> , 2012, 8, 15.	1.4	10
159	A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 395-409.	0.8	111
160	Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid- $\beta$ peptide in mice. <i>Behavioural Brain Research</i> , 2011, 225, 222-229.	1.2	131
161	Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF- $\alpha$ and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation. <i>The Open Biochemistry Journal</i> , 2011, 5, 37-44.	0.3	25
162	Cholinesterase Inhibitors Improve Both Memory and Complex Learning in Aged Beagle Dogs. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 143-155.	1.2	38

#	ARTICLE	IF	CITATIONS
163	Phenserine Efficacy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1201-1208.	1.2	62
164	Targets for AD treatment: conflicting messages from $\beta$ -secretase inhibitors. <i>Journal of Neurochemistry</i> , 2011, 117, 359-374.	2.1	59
165	Tumor necrosis factor $\alpha$ synthesis inhibitor, 3,6-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , 2011, 118, 1032-1042.	2.1	87
166	The alpha-synuclein 5' untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. <i>Journal of Neural Transmission</i> , 2011, 118, 493-507.	1.4	56
167	Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF $\alpha$ inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3965-3972.	1.4	21
168	Extension of Lifespan in <i>C. elegans</i> by Naphthoquinones That Act through Stress Hormesis Mechanisms. <i>PLoS ONE</i> , 2011, 6, e21922.	1.1	76
169	Rivastigmine Lowers $A\beta$ and Increases sAPP $\alpha$ Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons. <i>PLoS ONE</i> , 2011, 6, e21954.	1.1	58
170	Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 391-403.	0.8	192
171	The KATP Channel Activator Diazoxide Ameliorates Amyloid- $\beta$ and Tau Pathologies and Improves Memory in the 3xTgAD Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 443-457.	1.2	101
172	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4687-4693.	1.4	29
173	Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. <i>Journal of Neurochemistry</i> , 2010, 112, 1316-1326.	2.1	170
174	Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. <i>Journal of Neurochemistry</i> , 2010, 113, 1621-1631.	2.1	111
175	GLP-1 Receptor Stimulation Reduces Amyloid- $\beta$ Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1205-1219.	1.2	273
176	Lost in Translation: Neuropsychiatric Drug Development. <i>Science Translational Medicine</i> , 2010, 2, 61rv6.	5.8	54
177	Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 682-692.	1.3	65
178	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1285-1290.	3.3	483
179	Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. <i>Biochemical Journal</i> , 2009, 417, 213-222.	1.7	28
180	Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. <i>International Journal of Molecular Sciences</i> , 2009, 10, 1226-1260.	1.8	75

#	ARTICLE	IF	CITATIONS
181	Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development. <i>Current Alzheimer Research</i> , 2009, 6, 79-81.	0.7	11
182	Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease. <i>Diabetes</i> , 2009, 58, 318-328.	0.3	160
183	A cellular model of inflammation for identifying TNF- $\alpha$ synthesis inhibitors. <i>Journal of Neuroscience Methods</i> , 2009, 183, 182-187.	1.3	42
184	Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease. <i>Journal of Chromatography A</i> , 2009, 1216, 2730-2738.	1.8	37
185	Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine. <i>Neurochemical Research</i> , 2008, 33, 745-753.	1.6	60
186	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. <i>Journal of Neural Transmission</i> , 2008, 115, 889-898.	1.4	57
187	Alzheimer's Disease Drug Development in 2008 and Beyond: Problems and Opportunities. <i>Current Alzheimer Research</i> , 2008, 5, 346-357.	0.7	65
188	Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 303-325.	1.2	125
189	Synergistic effect of apolipoprotein E $\epsilon$ 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 289-298.	0.7	49
190	Dissociation Between the Potent $\beta$ -Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine. , 2008, , 445-462.		2
191	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12506-12511.	3.3	87
192	The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid- $\beta$ Peptide Levels in Cell Culture and Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 386-396.	1.3	122
193	TNF- $\alpha$ ; Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. <i>Current Alzheimer Research</i> , 2007, 4, 378-385.	0.7	178
194	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. <i>Experimental Neurology</i> , 2007, 203, 293-301.	2.0	166
195	Preclinical Investigation of the Topical Administration of Phenserine: Transdermal Flux, Cholinesterase Inhibition, and Cognitive Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 353-361.	1.3	14
196	Apoptotic and behavioral sequelae of mild brain trauma in mice. <i>Journal of Neuroscience Research</i> , 2007, 85, 805-815.	1.3	88
197	Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. <i>Journal of Neurochemistry</i> , 2007, 100, 1421-1429.	2.1	133
198	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease. <i>NeuroMolecular Medicine</i> , 2007, 9, 157-168.	1.8	14

#	ARTICLE	IF	CITATIONS
199	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease. <i>NeuroMolecular Medicine</i> , 2007, 9, 157-168.	1.8	3
200	Inhibition of Human Acetyl- and Butyrylcholinesterase by Novel Carbamates of (âˆ“)- and (+)-Tetrahydrofurobenzofuran and Methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2174-2185.	2.9	74
201	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006, 1760, 200-206.	1.1	35
202	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-âˆ“2 protein precursor and amyloid-âˆ“2 peptide levels, and lowers neuronal cell viability in culture: A role in Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 9-16.	1.2	10
203	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 43-51.	1.2	40
204	A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis. <i>Current Alzheimer Research</i> , 2006, 3, 81-90.	0.7	67
205	Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-âˆ“2 Peptide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 855-862.	1.3	39
206	In Vivo Biological Activity of Exendin (1âˆ“30). <i>Endocrine</i> , 2005, 27, 001-010.	2.2	16
207	Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects. <i>Current Alzheimer Research</i> , 2005, 2, 483-492.	0.7	39
208	Cholinesterases: Roles in the Brain During Health and Disease. <i>Current Alzheimer Research</i> , 2005, 2, 307-318.	0.7	303
209	An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 281-290.	0.7	118
210	Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 377-385.	0.7	113
211	Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer Aâˆ“amyloid peptide in rodent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17213-17218.	3.3	629
212	Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepineâˆ“†. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 986-994.	2.9	53
213	Syntheses of Tetrahydrofurobenzofurans and Dihydropyridomethanobenzodioxepines from 5-Hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and Ring Expansion under Reductive Conditions on Treatment with Hydrides. <i>Journal of Organic Chemistry</i> , 2005, 70, 6171-6176.	1.7	19
214	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitorsâˆ“†. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1919-1929.	2.9	65
215	Presence of a âˆ“CAGA boxâˆ“ in the APP gene unique to amyloid plaqueâˆ“forming species and absent in all APLP âˆ“1/2 genes: implications in Alzheimer's disease. <i>FASEB Journal</i> , 2004, 18, 1288-1290.	0.2	45
216	New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-âˆ“ Inhibitors, and GLP-1 Receptor Agonists. <i>Annals of the New York Academy of Sciences</i> , 2004, 1035, 290-315.	1.8	91

#	ARTICLE	IF	CITATIONS
217	Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. <i>Experimental Neurology</i> , 2004, 190, 133-144.	2.0	49
218	Lethal weapon: amyloid $\beta$ -peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 581-587.	1.5	22
219	Acetylcholinesterase and Its Inhibition in Alzheimer Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 141-149.	0.2	122
220	A New Alzheimer's Disease Interventive Strategy: GLP-1. <i>Current Drug Targets</i> , 2004, 5, 565-571.	1.0	102
221	Cholesterol and Alzheimer's Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors. <i>Current Drug Targets</i> , 2004, 5, 517-528.	1.0	57
222	Thalidomide-based TNF- $\alpha$ inhibitors for neurodegenerative diseases. <i>Acta Neurobiologiae Experimentalis</i> , 2004, 64, 1-9.	0.4	33
223	p53 is Present in Synapses Where it Mediates Mitochondrial Dysfunction and Synaptic Degeneration in Response to DNA Damage, and Oxidative and Excitotoxic Insults. <i>NeuroMolecular Medicine</i> , 2003, 3, 159-172.	1.8	67
224	Glucagon-like peptide-1 decreases endogenous amyloid- $\beta$ peptide ( $A\beta$ ) levels and protects hippocampal neurons from death induced by $A\beta$ and iron. <i>Journal of Neuroscience Research</i> , 2003, 72, 603-612.	1.3	309
225	Thiothalidomides: A Novel Isosteric Analogues of Thalidomide with Enhanced TNF- $\alpha$ Inhibitory Activity. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5222-5229.	2.9	78
226	The glucagon-like peptides: a double-edged therapeutic sword?. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 377-383.	4.0	102
227	The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. <i>Regulatory Peptides</i> , 2003, 114, 153-158.	1.9	54
228	Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 2835-2841.	4.3	97
229	A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimer's Disease. <i>Current Drug Targets</i> , 2003, 4, 97-112.	1.0	198
230	Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 881-888.	1.3	318
231	An Iron-responsive Element Type II in the 5'-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript. <i>Journal of Biological Chemistry</i> , 2002, 277, 45518-45528.	1.6	474
232	A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 958-966.	1.3	260
233	The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 487-496.	1.2	85
234	Novel p53 Inactivators with Neuroprotective Action: Syntheses and Pharmacological Evaluation of 2-Imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-Imino-2,3,4,5,6,7-hexahydrobenzoxazole Derivatives. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5090-5097.	2.9	104

#	ARTICLE	IF	CITATIONS
235	p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. <i>Annals of Neurology</i> , 2002, 52, 597-606.	2.8	198
236	Current drug targets for Alzheimer's disease treatment. <i>Drug Development Research</i> , 2002, 56, 267-281.	1.4	181
237	Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy. <i>International Psychogeriatrics</i> , 2002, 14, 77-91.	0.6	351
238	Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease. <i>NeuroMolecular Medicine</i> , 2002, 1, 1-32.	1.8	181
239	Insertion of an N-Terminal 6-Aminohexanoic Acid after the 7 Amino Acid Position of Glucagon-Like Peptide-1 Produces a Long-Acting Hypoglycemic Agent. <i>Endocrinology</i> , 2001, 142, 4462-4468.	1.4	28
240	Methyl Analogues of the Experimental Alzheimer Drug Phenserine:â€‰ Synthesis and Structure/Activity Relationships for Acetyl- and Butyrylcholinesterase Inhibitory Action. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4062-4071.	2.9	87
241	A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. <i>Journal of Neurochemistry</i> , 2001, 77, 220-228.	2.1	316
242	Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine. <i>Biochemical Pharmacology</i> , 2000, 60, 561-570.	2.0	59
243	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. <i>Endocrinology</i> , 2000, 141, 1936-1941.	1.4	271
244	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. <i>Endocrinology</i> , 2000, 141, 1936-1941.	1.4	99
245	Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Diseaseâ€‰. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1855-1861.	2.9	207
246	Syntheses and Anticholinesterase Activities of (3aS)-N,N8-Bisnorphenserine, (3aS)-N1,N8-Bisnorphysostigmine, Their Antipodal Isomers, and Other Potential Metabolites of Phenserine. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 2371-2379.	2.9	30
247	Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by a Novel Derivative of Physostigmine: Phenserine. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 180-185.	1.0	43
248	Total Syntheses and Anticholinesterase Activities of (3aS)-N(8)-Norphysostigmine, (3aS)-N(8)-Norphenserine, Their Antipodal Isomers, and OtherN(8)-Substituted Analoguesâ€‰. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2895-2901.	2.9	58
249	Cognitive Enhancement.. <i>Annals of the New York Academy of Sciences</i> , 1996, 786, 348-361.	1.8	38
250	Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. <i>NeuroReport</i> , 1995, 6, 481-484.	0.6	46
251	Phenserine and ring C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 1995, 15, 3-31.	5.0	188
252	Total Synthesis of Racemic and Optically Active Compounds Related to Physostigmine and Ring-C Heteroanalogues from 3-[2?-(dimethylamino)ethyl]2,3-dihydro-5-methoxy-1,3-dimethyl-1H-indo l-2-ol. <i>Helvetica Chimica Acta</i> , 1994, 77, 1412-1422.	1.0	17

#	ARTICLE	IF	CITATIONS
253	Rodent models of memory dysfunction in Alzheimer's disease and normal aging: Moving beyond the cholinergic hypothesis. <i>Life Sciences</i> , 1994, 55, 2037-2049.	2.0	64
254	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 40, 387-397.	1.3	113
255	Physovenines: Efficient Synthesis of (?) - and (+) -Physovenine and Synthesis of Carbamate Analogues of (?) -Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. <i>Helvetica Chimica Acta</i> , 1991, 74, 761-766.	1.0	38
256	Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 263-268.	1.1	92
257	Tight binding dopamine reuptake inhibitors as cocaine antagonists. <i>FEBS Letters</i> , 1989, 257, 341-344.	1.3	53
258	Optimizing drug delivery to brain tumors. <i>Cancer Treatment Reviews</i> , 1987, 14, 1-28.	3.4	124